Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Breakthough stem cell therapy could reverse chronic canine illness
Doctors already use stem cells to fight some forms of cancer and blood-related conditions in humans.
Study paves the way to new therapies and potenatial cures.

Researchers in Japan have devised a novel method to induce stem cell generation from dog blood samples.

Scientists at Osaka Prefecture University hope to use the technique to advance regenerative therapies in veterinary medicine. This could mean that vets may one day be able to reverse conditions in dogs previously thought to be incurable.

Doctors already use stem cells to fight some forms of cancer and blood-related conditions in humans, such as leukaemia and lymphoma. Stem cells can differentiate and mature into many specialised cell types, known as 'pluripotency'.

By transplanting stem cells and guiding their differentiation into desired cell types, doctors can repair damaged tissue and reverse the course of complex conditions. But while this technique has been widely studied in humans, it has not been thoroughly explored in dogs.

In this study, the scientists worked on isolating induced pluripotent stem cells (iPSCs) from canine blood samples. iPSCs are a type of stem cell that can be “programmed” from a developed (or “differentiated”) cell by introducing a specific set of genes into them. 

These genes code for proteins called 'transcription factors' that induce the change from a 'differentiated' to a 'pluripotent' stem cell, which then can mature into various cell types. The scientists found that iPSCs can proliferate very rapidly, thereby providing a reliable supply of suitable stem cells for regenerative therapies.

Study leader Shingo Hatoya, an Associate Professor from Osaka Prefecture University, said: “We successfully established an efficient and easy generation method of canine iPSCs from peripheral blood mononuclear cells”. He added that the findings have great significance for veterinary medicine and that, one day, “it may be possible to perform regenerative medicinal treatments in dogs.” 

Interestingly, the study authors believe that further research into regenerative therapies for canines might have some ripple effects for human medicine. Professor Hatoya added: "Dogs share the same environment as humans and spontaneously develop the same diseases, particularly genetic diseases." 

Translating findings from one field to another could pave the way to new treatments or even cures for some infections that continue to plague humanity. The findings are published in the journal Stem Cells and Development

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.